Azathioprine-induced severe cholestatic hepatitis in patient carrying TPMT*3C polymorphism

Pharmacy World and Science

Volumn 32, Issue 6, 2010, Pages 701-703

  Ben Salem, Chaker ^a   Ben Salah, Lynda ^a   Belajouza, Colandane ^b   Bouraoui, Kamel ^a  

^a UNIVERSITY OF SOUSSE   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Adverse drug reaction; Azathioprine; AZT; Cholestatic hepatitis; Pharmacogenetics; TPMT variants

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE;

ADULT; ALLELE; ARTICLE; CASE REPORT; CHOLESTATIC HEPATITIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; JAUNDICE; LABORATORY TEST; LIVER FUNCTION TEST; MALE; PEMPHIGUS FOLIACEUS; PRURITUS;

ADULT; AZATHIOPRINE; CHOLESTASIS, INTRAHEPATIC; FOLLOW-UP STUDIES; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; MALE; METHYLTRANSFERASES; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX;

EID: 79952703703     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-010-9443-4     Document Type: Article

References (10)

1. Fernando SL, Broadfoot AJ. Treatment options for pemphigus foliaceus. G Ital Dermatol Venereol. 2009;144:363-77.
2. Higgs JE, Ayne PK, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010;11:177-88.
3. Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L. Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut. 1991;32:715-7.
4. Romagnuolo J, Sadowski DC, Lalor E, Jewell L, Thomson AB. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol. 1998;12(7):479-83. (Pubitemid 28495463)
5. Du Vivier A, Munro DD, Verbov J. Treatment of psoriasis with azathioprine. Br Med J. 1974;1:49-51.
6. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R. Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs. Gastroenterol Clin Biol. 2004;28:720-59. (Pubitemid 39318162)
7. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol. 2003;55:560-9. (Pubitemid 36783197)
8. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999;8:367-70. (Pubitemid 29054280)
9. Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9:37-42.
10. Xin HW, Xiong H, Wu XC, Li Q, Xiong L, Yu AR. Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients. Eur J Clin Pharmacol. 2009;65:249-55.